Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/57591
IN VITRO ACTIVITY OF CIPROFLOXACIN, OFLOXACIN, LEVOFLOXACIN, SPARFLOXACIN AND GATIFLOXACIN AGAINST MULTIDRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS IN RIO DE JANEIRO, BRAZIL
Alternative title
Activité in vitro de la ciprofloxacine ofloxacine, lévofloxacine, sparfloxacine et gatifloxacine sur huit souches de Mycobacterium tuberculosis multirésistantes tuberculosis à Rio de Janeiro BrésilAffilliation
Fundação Oswaldo Cruz. Instituto de Pesquisas Clínicas Evandro Chagas. Instituto de Bacteriologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisas Clínicas Evandro Chagas. Instituto de Bacteriologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisas Clínicas Evandro Chagas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos (FarManguinhos). Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisas Clínicas Evandro Chagas. Instituto de Bacteriologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisas Clínicas Evandro Chagas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos (FarManguinhos). Rio de Janeiro, RJ, Brasil.
Abstract
The aim of this study was to determine the in vitro activity of fluoroquinolones against clinical strains of Mycobacterium tuberculosis identified in Rio de Janeiro, Brazil, with the highest number of new cases in this country. Accurate susceptibility data for the treatment of TB increases treatment success rates, while decreasing the spread of resistant strains and the rate of developing resistance to additional drugs. In this context, this study provides an important starting point by testing the susceptibility of M. tuberculosis to a class of drugs likely to be of increasing importance in treating TB infections.
Share